We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · November 04, 2020

Tideglusib for Congenital and Childhood-Onset Myotonic Dystrophy Type 1

Pediatric Neurology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Pediatric Neurology
A Phase 2 Study of AMO-02 (Tideglusib) in Congenital and Childhood-Onset Myotonic Dystrophy Type 1 (DM1)
Pediatr. Neurol. 2020 Nov 01;112(xx)84-93, J Horrigan, TB Gomes, M Snape, N Nikolenko, A McMorn, S Evans, A Yaroshinsky, O Della Pasqua, S Oosterholt, H Lochmüller

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading